Another example is sunitinib, a dual vascular endothelial growth factor (VEGF) and PDGF receptor inhibitor approved by the FDA for the treatment of renal cell carcinoma. The gene discussed is VEGFA; the disease is hereditary clear cell renal cell carcinoma.